Revolution Medicines
Revolution Medicines is seeking an Associate Director for Clinical Operations to oversee the execution and management of clinical trials for novel oncology therapies. The role involves leading CRO oversight, managing global clinical trials, and ensuring compliance with regulatory standards.
Headquarters
Redwood City, California, United States
Company Size
201-500 employees
Founded
2014
Revolution Medicines (RevMed) is a biopharmaceutical company dedicated to discovering, developing, and delivering novel targeted medicines for patients with cancer. Their mission focuses specifically on "revolutionizing treatment for patients with RAS‑addicted cancers" through precision-targeted therapies. The company emphasizes a science-driven, end-to-end approach from discovery to delivery. RevMed brands its team as "Revolutionaries" committed to transforming outcomes for people with RAS‑driven tumors.
Victory Capital Management Inc. Trims Stock Holdings in Revolution Medicines, Inc. $RVMD
13 hours ago
Revolution Medicines Trials, Funding Capacity And Insider Moves Shape Risk Outlook
5 days ago
Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
2 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Revolution Medicines.
Revolution Medicines, Inc. (RVMD) Net Loss Widens amid Progress on Clinical Trial Programs
1 week ago
Senior Enterprise Systems Administrator
CG Oncology
Senior Project Manager - Clinical Trials
Precision for Medicine
Senior Project Manager - Clinical Trials
Precision for Medicine
Associate, Study Management III
AbbVie
Associate, Study Management II or Ⅲ
AbbVie
Clinical Research Associate
Monte Rosa Therapeutics, Inc